AMGN
Amgen Inc.
Healthcare · Drug Manufacturers - General · United States · Stock
Score Breakdown
Scored for Aggressive Growth profile
Sub-scores are 0–20 each; Model Score is weighted by your selected investment goal. How it works →
Why Ranked Here
- The combined weight of strong profitability (16.0/20) and strong momentum (16.0/20) provides the core foundation of the 58.6 score, reflecting real operational quality visible in SEC filing data.
- The dividend sub-score of 12.5/20 adds meaningful incremental scoring by confirming that FCF generation is sufficient to support and grow shareholder distributions, which is a positive quality signal in the filing data.
- The growth sub-score of 15.0/20 contributes positively, indicating year-over-year expansion in revenue, net income, and/or EPS metrics as reported in the FY2025 10-K, consistent with a business that is growing even as it digests a transformative acquisition.
Why Not Higher
- The financial health sub-score of 6.0/20 is the primary ceiling on the total score; a near-floor reading on leverage and interest coverage directly suppresses what would otherwise be a much higher composite result given the strength in other dimensions.
- The theme sub-score of 0.0/20 removes up to 20 potential points from the model, meaning Amgen captures no benefit from macro-theme alignment, a gap that would need to be closed through new product disclosures or strategic pivots that register in future filings.
Data Confidence
10 / 10
Very High — full data coverage
Research Summary
AI-generated analysis reflects data and conditions as of the report date shown above. Verify any specific figures through primary sources before acting on this analysis.
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California, with a portfolio of blockbuster biologics spanning oncology, cardiovascular disease, inflammation, bone health, and rare diseases. Its flagship products include Enbrel, Otezla, Repatha, EVENITY, and the newer obesity/cardiometabolic candidate MariTide, alongside a growing biosimilars segment. The company's FY2025 10-K filing reveals a business in operational transition following the landmark acquisition of Horizon Therapeutics in 2023, which significantly expanded its rare disease footprint but also added material debt to the balance sheet. The model scored Amgen 58.6/100, reflecting genuinely strong profitability (16.0/20) and momentum (16.0/20) alongside solid dividend metrics (12.5/20), but weighed down by a notably weak financial health sub-score (6.0/20) that signals the leverage burden post-Horizon, and a zero theme score (0.0/20) indicating no detected macro-theme tailwinds in the filing data. Growth scores (15.0/20) are respectable but not exceptional, suggesting the top-line is expanding rather than accelerating. The core research tradeoff is between Amgen's durable cash generation, wide operating margins, and disciplined dividend growth on one side, versus a heavily leveraged balance sheet and limited interest coverage headroom on the other — a profile that rewards execution but punishes any revenue disappointment.
Plain English
Amgen is a giant biotech company that makes medicines for serious conditions like cancer, arthritis, high cholesterol, and rare diseases. The model score of 58.6 out of 100 says it is a decent but not exceptional research candidate — its profits and recent earnings momentum are genuinely strong, but the company took on a lot of debt from a major acquisition and that is weighing the score down significantly. The High risk rating reflects that combination of financial leverage and the inherent unpredictability of drug pipelines, patent cliffs, and regulatory outcomes. Researchers with an aggressive growth goal profile will find the most alignment here, while those seeking a lower-risk profile should be aware the balance sheet warrants careful monitoring.
Bull Case vs. Bear Case
Bull Case
- Amgen's profitability sub-score of 16.0/20 reflects best-in-class operating and net margins typical of a mature biotech with established blockbuster products generating durable, high-margin cash flows.
- The momentum sub-score of 16.0/20 indicates sequential quarterly improvement in revenue, earnings, and/or margins within the FY2025 filing period, suggesting the post-Horizon integration is beginning to deliver operational lift.
- A dividend sub-score of 12.5/20 points to strong free cash flow coverage of dividends, a consistent DPS growth track record, and a payout ratio that does not appear to strain FCF generation, reinforcing confidence in capital return sustainability.
Bear Case
- The financial health sub-score of just 6.0/20 is the single most significant drag on the overall model score, reflecting elevated leverage ratios and compressed interest coverage resulting from the debt-funded Horizon Therapeutics acquisition.
- The theme sub-score of 0.0/20 means the filing did not register exposure to any of the model's tracked macro themes, suggesting Amgen's current portfolio mix and disclosure language do not align with high-momentum structural growth narratives that tend to drive aggressive re-rating.
- A growth sub-score of 15.0/20, while above mid-range, indicates revenue and EPS growth that is solid rather than accelerating, which may limit upside surprise potential if key products face biosimilar competition or slower-than-expected uptake of pipeline assets like MariTide.
What Could Change the Picture
Bullish Triggers
- A material improvement in the financial health sub-score — driven by sustained debt reduction, improved interest coverage ratios, or leverage metrics returning to pre-Horizon levels as evidenced in future 10-K filings — would be the single largest potential score upgrade catalyst.
- Evidence in a future filing of product pipeline assets (such as MariTide in obesity/cardiometabolic) generating meaningful revenue contribution could lift the growth sub-score above 15.0 and begin registering macro-theme exposure, potentially unlocking a non-zero theme score.
Bearish Triggers
- Any future filing showing deterioration in operating or net margins — signaling integration costs, pipeline write-downs, or pricing pressure on core biologics from biosimilar competition — would weaken the profitability sub-score that currently anchors the thesis.
- A reversal in the momentum sub-score, indicated by sequential quarterly declines in revenue or earnings in a future 10-K, would undercut the key forward-looking signal and raise questions about whether the post-acquisition growth trajectory is durable.
Red Flags
- The financial health sub-score of 6.0/20 is a material concern derived directly from the filing and reflects a leverage and interest coverage profile that leaves limited buffer against an earnings shortfall or rising refinancing costs.
- A theme score of 0.0/20 combined with a high risk rating suggests the model finds no identifiable macro tailwind to help offset the balance sheet risk, making Amgen's outlook more dependent on company-specific execution than sector-level momentum.
Risk Profile
High RiskThe High risk rating for Amgen reflects the combination of a heavily leveraged post-acquisition balance sheet — as evidenced by the 6.0/20 financial health sub-score — and the inherent binary risks of a drug manufacturer, including patent expirations, regulatory decisions, and clinical trial outcomes that can materially shift the earnings trajectory with limited warning.
Key Catalysts to Watch
The key factors to monitor in future SEC filings include the pace of Horizon Therapeutics debt repayment and its impact on the financial health sub-score, as well as commercial launch data for pipeline assets like MariTide that could meaningfully shift both the growth and theme sub-scores.
This report is for educational and research purposes only. It does not constitute financial, investment, legal, or tax advice — always conduct your own due diligence before making investment decisions.